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Abstract

Research Question

➢ The long-term use of oral anticoagulants is common among highrisk patient populations for the prevention of thromboembolic
events such as stroke, pulmonary embolism, etc. It is estimated that
15-20% of chronically anticoagulated patients will undergo a
surgery or procedure that will require anticoagulation interruption
annually. During this interruption period, “bridging” anticoagulant
therapy is often utilized with unfractionated heparin or lowmolecular weight heparin to ensure adequate anticoagulation is
achieved. However, there has been an ongoing debate whether or
not the benefits of perioperative anticoagulant bridging therapy
outweigh its risks. This literature review focuses on whether or not
forgoing anticoagulant bridging therapy increases the risk of
peri/postoperative thromboembolic events. It also focuses on the
whether or not initiating bridging therapy places patients at a higher
risk for postoperative bleeding. Finally, it focusses on the current
recommendations and whether or not utilization of individualized
risk assessment tools increases efficacy and safety in regards to
determining appropriate bridging therapy. The results of this
literature review conclude that in low-risk patients there is sufficient
evidence to support that non-bridging therapy is non-inferior to
bridging therapy in the prevention of peri/postoperative
thromboembolic events. There is also evidence to support that
anticoagulant bridging therapy may place low-risk patients at a
significantly higher risk for peri/postoperative bleeding events.
Finally, there appears to be sufficient evidence to support the use of
individualized risk assessment tools to help guide clinicians in their
decisions regarding anticoagulant bridging therapy.

➢ Does forgoing perioperative anticoagulant bridging therapy in
patients who are chronically anticoagulated place them at a higher
risk for a postoperative thromboembolic event vs those patients
who initiate bridging therapy?
➢ Does initiating perioperative anticoagulant bridging therapy in
patients who are chronically anticoagulated place them at a higher
risk for a major intra/postoperative bleeding event vs those
patients who forgo bridging therapy?
➢ Should patients undergoing perioperative anticoagulant
interruption be assessed using individualized risk assessment tools
vs standardized bridging protocols to determine the need for
anticoagulant bridging therapy?

Introduction
➢ Oral anticoagulants are commonly used long-term in patients with
atrial fibrillation, a history of a mechanical heart valve, or a recent
history of thromboembolic events.
➢ It is estimated that 15-20% of chronically anticoagulated patients will
undergo an elective or emergent surgery or procedure that will require
anticoagulation interruption annually (Garwood et al., 2017).
➢ During this interruption period, “bridging” anticoagulant therapy is
often utilized with unfractionated heparin or low-molecular weight
heparin to ensure adequate anticoagulation is achieved and to reduce
the risk of a thromboembolic event perioperatively (Ayoub et al.,
2016).
➢ Current debate whether thromboembolic events caused by
perioperative anticoagulant interruption posts a larger risk for patients
than intra/postoperative bleeding for those who initiate bridging
therapy (Douketis et al., 2015).

Statement of the Problem
➢ There is currently a lack of updated evidence-based guidelines and
recommendations in regards to indications for perioperative bridging
therapy.
➢ The most recent antithrombotic guidelines come from the American
College of Chest Physicians (ACCP) in 2012.
➢ Current guidelines are a low-level recommendation (Level 2-C)
➢ To date, there remains to be an anticoagulant bridging therapy that is
universally accepted which tailors an individual’s thromboembolic
risk factors (Pengo et al., 2009).
➢ There is a need for additional high-level studies, and evidence-based
guidelines to help guide clinicians.

Literature Review

Discussion
➢ Siegal et al. (2012) found an increased risk in overall bleeding events
was demonstrated in bridged patients compared to non-bridged
patients (5.4 vs 3.6, 95% CI). Anticoagulant bridging therapy was
associated with an overall increased risk of bleeding events in 13
studies (odds ratio, 5.40; 95% CI, 3.00-9.74) and major bleeding
events in five studies (odds ratio, 3.60; 95% CI, 1.52-8.50).
➢ According to the Ayoub et al. (2016) meta-analysis there was a
significantly reduced risk in postoperative bleeding identified in the
non-bridging group as compared to the bridging group (OR, 0.41;
95% CI, 0.24-0.68; P=0.0006).
➢ Steinberg et al. (2015) found that the use of anticoagulant bridging
therapy in patients with atrial fibrillation resulted in significantly
higher overall bleeding risks (5.0% vs 1.3%; adjusted odds ratio, 3.84;
P<0.0001).

Anticoagulant Bridging Therapy: Thromboembolic Risks

Individualized Risk Assessments

➢ Douketis et al. (2016) found from their BRIDGE trial that the
placebo group was non-inferior when compared to the dalterparin
group in reducing thromboembolic risk. Incidence rate of 0.4%
(4 of 918) in placebo group compared to 0.3% (3 of 895) in the
dalterparin group (risk difference, 0.1 percentage points, 95%
confidence interval [CI], -0.6 to 0.8; P=0.01 for noninferiority).
➢ Bouillon et al. (2016) found no statistically significant difference
in the occurrence of stroke/systemic embolism between the
bridged and non-bridged groups at one-month of follow-up or
later (HR 0.97, 95% CI 0.68 – 1.37, P=0.841 from 0-1 months
follow-up, HR 0.98, 95% CI 0.67-1.43, P=0.899 from 2-3 months
of follow-up).
➢ Ayoub et al. (2016) found no statistically significant difference in
all-cause mortality (OR, 1.29; 95% CI, 0.15-11.52; P=0.82),
cerebral vascular accident (OR, 0.93; 95% CI, 0.34-2.51; P=0.88),
or thromboembolic events (OR, 0.72; 95% CI, 0.72-2.80; P=0.64)
between the heparin bridging group and the non-bridging group at
30 days and up to 3 months.

➢ Palaniswamy and Selvaraj (2011) found that patients with atrial
fibrillation who undergo perioperative interruption of oral
anticoagulation should be stratified based on their risk of
thromboembolic event compared to bleeding.
➢ Pengo et al. (2009) demonstrated that tailoring anticoagulant bridging
therapy to a patient’s thromboembolic risk index was both an effective
and safe strategy.
➢ Oprea, Noto, and Halaszynski (2016) performed a risk stratification
review which stressed the importance of basing treatment with
anticoagulant bridging therapy on patient-specific conditions.

➢ Forgoing bridging was associated with a risk of bleeding that was
significantly lower than the risk associated with bridging
➢ Douketis et al. (2016) found that “bridging conferred a risk of major
bleeding that was nearly triple the risk associated with no bridging”
➢ Thromboembolic risk should be weighed against the bleeding risk
associated with the procedure
➢ According to Siegel et al. (2012) patients receiving anticoagulant
bridging perioperatively were at a 3-5-fold increase in overall and
major bleeding events compared to patients who received no bridging
therapy.
➢ Individualized risk assessment scores should be utilized when
determining risk prior to administration of bridging therapy.

Applicability to Clinical
Practice
➢ Forgoing bridging therapy may be non-inferior to bridging therapy in
regards to thromboembolic prevention in low-risk patients.
➢ Bridging therapy is associated with a significantly higher risk of
bleeding events compared to non-bridging therapy.
➢ Clinician's should utilize individualized risk assessment calculators
(CHADS₂, HAS-BLED) to calculate a patients thromboembolic and
bleeding risks to help guide clinicians in their decisions to use or
forgo anticoagulant bridging therapy.

➢ Ono et al. (2016) demonstrated similar incidences between the
HBA and non-HBA groups for exogenous blood transfusion
(23.3% vs 19.4%, P = 0.587) and thromboembolic events (4.1% vs
3.2%, P =0.755). The results demonstrate no significant rise in
thromboembolic events with the non-HBA group as compared to
the HBA group.
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